Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.
Plus: Their stigma-busting initiative gets a shout-out from POZ’s Best Celebrity Advocate 2019.
The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.
A clinical trial compared injectable cabotegravir given every eight weeks versus daily Truvada for HIV prevention.
Bonus: Your donations to the Broadway Cares effort Emergency Grants for Pandemic Relief will be matched by Gilead Sciences.
A majority of women interviewed in a small study expressed a preference for monthly injectable treatment over daily pills.
Here’s how local community organizations and HIV scientists alike can apply for grants from the HIV health care company.
The Food and Drug Administration declined approval of ViiV Healthcare’s injectable HIV regimen Cabenuva.
ViiV applies for FDA approval of HIV drug fostemsavir
The FDA recently held up the U.S. approval based on concerns over the monthly injectable regimen’s manufacturing.
Whether given every four or eight weeks, long-acting injections of cabotegravir and rilpivirine suppressed HIV equally well.
Plus: Top 10 philanthropic funders of HIV, according to the latest report from Funders Concerned About AIDS
The agency expressed concerns about the monthly injectable regimen’s chemistry and manufacturing controls.
Here are the HIV treatment news stories with the most views this year.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.